{"brief_title": "A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia", "brief_summary": "To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).", "detailed_description": "Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate. Patients are followed for 1 month.", "condition": ["Pneumonia, Pneumocystis Carinii", "HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Trimetrexate glucuronate", "Leucovorin calcium"], "criteria": "Inclusion Criteria Patients must have: - Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry. - Serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of PCP, OR a documented history of such intolerance during a prior episode. - Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Patients with the following prior conditions are excluded: History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate.", "gender": "All", "minimum_age": "13 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Acquired Immunodeficiency Syndrome", "mesh_term": ["HIV Infections", "Pneumonia", "Pneumonia, Pneumocystis", "Levoleucovorin", "Trimetrexate"], "id": "NCT00002103"}